MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41591-022-01789-0

Медицинская библиотека · Nature medicine · 2022

Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.

Rivellese Felice, Surace Anna E A, Goldmann Katriona, Sciacca Elisabetta, Çubuk Cankut, Giorli Giovanni, John Christopher R, Nerviani Alessandra, Fossati-Jimack Liliane, Thorborn Georgina, Ahmed Manzoor, Prediletto Edoardo, Church Sarah E, Hudson Briana M, Warren Sarah E, McKeigue Paul M, Humby Frances, Bombardieri Michele, Barnes Michael R, Lewis Myles J, Pitzalis Costantino, R4RA collaborative group

Клиническое исследование IV фазыСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased tissue. Approximately 40% of patients do not respond to individual biologic therapies and 5-20% are refractory to all. In a biopsy-based, precision-medicine, randomized clinical trial in RA (R4RA; n = 164), patients with low/absent synovial B cell molecular signature had a lower response to rituximab (anti-CD20 monoclonal antibody) compared with that to tocilizumab (anti-IL6R monoclonal antibody) although the exact mechanisms of response/nonresponse remain to be established. Here, in-depth histological/molecular analyses of R4RA synovial biopsies identify humoral immune response gene signatures associated with response to rituximab and tocilizumab, and a stromal/fibroblast signature in patients refractory to all medications. Post-treatment changes in synovial gene expression and cell infiltration highlighted divergent effects of rituximab and tocilizumab relating to differing response/nonresponse mechanisms. Using ten-by-tenfold nested cross-validation, we developed machine learning algorithms predictive of response to rituximab (area under the curve (AUC) = 0.74), tocilizumab (AUC = 0.68) and, notably, multidrug resistance (AUC = 0.69). This study supports the notion that disease endotypes, driven by diverse molecular pathology pathways in the diseased tissue, determine diverse clinical and treatment-response phenotypes. It also highlights the importance of integration of molecular pathology signatures into clinical algorithms to optimize the future use of existing medications and inform the development of new drugs for refractory patients.

Для цитирования: Rivellese Felice, Surace Anna E A, Goldmann Katriona, Sciacca Elisabetta, Çubuk Cankut, Giorli Giovanni, John Christopher R, Nerviani Alessandra, Fossati-Jimack Liliane, Thorborn Georgina, Ahmed Manzoor, Prediletto Edoardo, Church Sarah E, Hudson Briana M, Warren Sarah E, McKeigue Paul M, Humby Frances, Bombardieri Michele, Barnes Michael R, Lewis Myles J, Pitzalis Costantino, R4RA collaborative group. Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.. Nature medicine. 2022. DOI: 10.1038/s41591-022-01789-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.